Studies in syngeneic cancer models have shown that CD47 mAbs can effectively inhibit tumor growth and that efficacy is dependent on macrophages, dendritic cells, T cells, and their interactions [237,244,246,247]. The gene discussed is CD47; the disease is neoplasm.